Abstract
In the present study, we investigated whether circulating cell-free microRNAs serve as potential biomarkers in epithelial ovarian cancer (EOC) patients. Circulating miR-373, miR-200a, miR-200b and miR-200c were quantified in a cohort of 60 EOC patients, 20 patients with benign ovarian diseases and 32 healthy women using quantitative TaqMan MicroRNA assays. The serum concentrations of cell-free miR-373, miR-200a, miR-200b and miR-200c were significantly higher in EOC patients than in healthy women (p = 0.0001). With a sensitivity of 83 % and a specificity of 100 %, the combination of miR-200a, miR-200b and miR-200c could differ between malignant and benign ovarian tumors (p = 0.0001). Elevated levels of these cell-free microRNAs could be detected in FIGO I–II and FIGO III–IV stages, grading G1-2 and G3 and lymph node-negative and -positive EOC. In conclusion, the increased serum levels of this microRNA panel have diagnostic value for distinguishing healthy controls and benign tumors from EOC.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Arroyo JD, Chevillet JR, Kroh EM et al (2011) Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 108:5003–5008
Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136:215–233
Calin GA, Sevignani C, Dumitru CD et al (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 101:2999–3004
Chen D, Dang BL, Huang JZ et al (2015) MiR-373 drives the epithelial-to-mesenchymal transition and metastasis via the miR-373-TXNIP-HIF1alpha-TWIST signaling axis in breast cancer. Oncotarget, Epub of print
Eichelser C, Flesch-Janys D, Chang-Claude J et al (2013) Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clin Chem 59:1489–1496
Eichelser C, Stuckrath I, Muller V et al (2014) Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget 5:9650–9663
Hu X, Macdonald DM, Huettner PC et al (2009) A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol 114:457–464
Jayson GC, Kohn EC, Kitchener HC et al (2014) Ovarian cancer. Lancet 384:1376–1388
Kan CW, Hahn MA, Gard GB et al (2012) Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer 12:627
Koutsaki M, Spandidos DA, Zaravinos A (2014) Epithelial-mesenchymal transition-associated miRNAs in ovarian carcinoma, with highlight on the miR-200 family: prognostic value and prospective role in ovarian cancer therapeutics. Cancer Lett 351:173–181
Krol J, Loedige I, Filipowicz W (2010) The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 11:597–610
Meinhold-Heerlein I, Hauptmann S (2014) The heterogeneity of ovarian cancer. Arch Gynecol Obstet 289:237–239
Muller V, Gade S, Steinbach B et al (2014) Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. Breast Cancer Res Treat 147:61–68
Muralidhar GG, Barbolina MV (2015) The miR-200 family: versatile players in epithelial ovarian cancer. Int J Mol Sci 16:16833–16847
Nakano H, Yamada Y, Miyazawa T et al (2013) Gain-of-function microRNA screens identify miR-193a regulating proliferation and apoptosis in epithelial ovarian cancer cells. Int J Oncol 42:1875–1882
Park SM, Gaur AB, Lengyel E et al (2008) The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 22:894–907
Rani S (2014) MicroRNA profiling of exosomes isolated from biofluids and conditioned media. Methods Mol Biol 1182:131–144
Schwarzenbach H, Nishida N, Calin GA et al (2014) Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol 11:145–156
Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, Liang S, Naylor TL, Barchetti A, Ward MR et al (2006) microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A 103:9136–9141
Zhang Y, Zhao FJ, Chen LL et al (2014) MiR-373 targeting of the Rab22a oncogene suppresses tumor invasion and metastasis in ovarian cancer. Oncotarget 5:12291–12303
Grant Support
This work was supported by the China Scholarship Council (201206170034), and the ERC (European Research Council) Advanced Investigator Grant (ERC-2010 AsG 20100317 DISSECT).
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this paper
Cite this paper
Meng, X., Müller, V., Milde-Langosch, K., Trillsch, F., Pantel, K., Schwarzenbach, H. (2016). Circulating Cell-Free miR-373, miR-200a, miR-200b and miR-200c in Patients with Epithelial Ovarian Cancer. In: Gahan, P., Fleischhacker, M., Schmidt, B. (eds) Circulating Nucleic Acids in Serum and Plasma – CNAPS IX. Advances in Experimental Medicine and Biology, vol 924. Springer, Cham. https://doi.org/10.1007/978-3-319-42044-8_1
Download citation
DOI: https://doi.org/10.1007/978-3-319-42044-8_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-42042-4
Online ISBN: 978-3-319-42044-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)